Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Significance: Pepducins are a class of biologics that allosterically control G protein-coupled receptor (GPCR) activity, but very little is known about their mode of action. Here, we report that ATI-2341, a pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), functions as a biased ligand, favoring Gαi activation over Gα13. Moreover, contrary to the natural CXCR4 agonist, stromal cell-derived factor-1α, ATI-2341 does not promote β-arrestin recruitment. In addition to revealing the selective signaling underlying ATI-2341 effects on hematopoietic cell mobilization, the study shows that pepducins are powerful tools offering perspectives for studying GPCR functional selectivity that could impact the development of drugs with fewer side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists
Wu, B., Chien, E. Y. T., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., Wells, P., Bi, F. C., et al. (2010) · Science · doi:10.1126/science.1194396 · Cited by 1,782 · cited 1×
“Given that CXCR4 has been shown to form homodimers (54, 55), it can be hypothesized that pepducins might act by modulating dimerization.”
BackgroundA highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)
Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A., & Springer, T. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1101 · Cited by 1,482 · cited 1×
“In recent studies, whereas SDF-1 was found to promote mobilization of B and T lymphocytes, ATI2341 did not lead to the mobilization of either lymphocyte type (18, 28, 58).”
BackgroundCXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
Burger, J. A., & Kipps, T. J. (2006) · Blood · doi:10.1182/blood-2005-08-3182 · Cited by 1,170
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951 · cited 1×
“To quantify this bias, we used a method (43) based on the Black and Leff operational model (44).”
MethodBoire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., & Kuliopulos, A. (2005) · Cell · doi:10.1016/j.cell.2004.12.018 · Cited by 838
Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Kenakin, T., & Christopoulos, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3954 · Cited by 740
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
Sun, X., Cheng, G., Hao, M., Zheng, J., Zhou, X., Zhang, J., Taichman, R. S., Pienta, K. J., & Wang, J. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9256-x · Cited by 727
Molecular Mechanism of β-Arrestin-Biased Agonism at Seven-Transmembrane Receptors
Reiter, E., Ahn, S., Shukla, A. K., & Lefkowitz, R. J. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105800 · Cited by 583
Azzi, M., Charest, P. G., Angers, S., Rousseau, G., Kohout, T., Bouvier, M., & Piñeyro, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1936664100 · Cited by 523
Self-citationTherapeutic potential of β-arrestin- and G protein-biased agonists
Whalen, E. J., Rajagopal, S., & Lefkowitz, R. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.11.004 · Cited by 510
A Simple Method for Quantifying Functional Selectivity and Agonist Bias
Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., & Novick, S. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200111m · Cited by 484 · cited 2×
“To quantify this bias, we used a method (43) based on the Black and Leff operational model (44).”
MethodGalés, C., Van Durm, J. J. J., Schaak, S., Pontier, S., Percherancier, Y., Audet, M., Paris, H., & Bouvier, M. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1134 · Cited by 459 · cited 3×
“These data are consistent with the notion that GPCRs may be precoupled to G protein, even before activation (41, 56, 57).”
BackgroundMethodSelf-citationQuantifying Ligand Bias at Seven-Transmembrane Receptors
Rajagopal, S., Ahn, S., Rominger, D. H., Gowen-MacDonald, W., Lam, C. M., DeWire, S. M., Violin, J. D., & Lefkowitz, R. J. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072801 · Cited by 388 · cited 3×
“This method was selected over other approaches that use the affinities derived from radioligand binding assays to determine the KA (51) because it has been found impractical to measure accurate binding affinities using pepducins (2).”
MethodSun, Y., Cheng, Z., Ma, L., & Pei, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207294200 · Cited by 382
The evasive nature of drug efficacy: implications for drug discovery
Galandrin, S., Oligny-Longpré, G., & Bouvier, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.005 · Cited by 363
Self-citationStroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis
Kryczek, I., Wei, S., Keller, E., Liu, R., & Zou, W. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00406.2006 · Cited by 329
Covic, L., Gresser, A. L., Talavera, J., Swift, S., & Kuliopulos, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022460899 · Cited by 314
Devine, S. M., Vij, R., Rettig, M., Todt, L., McGlauchlen, K., Fisher, N., Devine, H., Link, D. C., Calandra, G., Bridger, G., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130179 · Cited by 308
Busillo, J. M., Armando, S., Sengupta, R., Meucci, O., Bouvier, M., & Benovic, J. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091173 · Cited by 281 · cited 7×
“CXCR4 is phosphorylated by PKC and GRK6 on Ser-324 and -325 (Ser-324/5) in response to SDF-1 (45).”
BackgroundMethodResultInfluentialSelf-citationPepducin-based intervention of thrombin-receptor signaling and systemic platelet activation
Covic, L., Misra, M., Badar, J., Singh, C., & Kuliopulos, A. (2002) · Nature Medicine · doi:10.1038/nm760 · Cited by 275
Trafficking of the HIV Coreceptor CXCR4
Orsini, M. J., Parent, J.-L., Mundell, S. J., & Benovic, J. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.31076 · Cited by 264 · cited 1×
“The results presented herein and previous studies clearly showed that phosphorylation of CXCR4 by GRK2 and GRK3 promotes β-arrestin recruitment (45, 52).”
ResultSelf-citationPercherancier, Y., Berchiche, Y. A., Slight, I., Volkmer-Engert, R., Tamamura, H., Fujii, N., Bouvier, M., & Heveker, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411151200 · Cited by 261 · cited 2×
“Given that CXCR4 has been shown to form homodimers (54, 55), it can be hypothesized that pepducins might act by modulating dimerization.”
BackgroundSelf-citationHIV and the chemokine system: 10 years later
Lusso, P. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600947 · Cited by 235 · cited 5×
“Proc Natl Acad Sci USA 108(20):8491–8496.”
BackgroundInfluentialBiased signalling and allosteric machines: new vistas and challenges for drug discovery
Kenakin, T. P. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01749.x · Cited by 233
'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage
Kaneider, N. C., Leger, A. J., Agarwal, A., Nguyen, N., Perides, G., Derian, C., Covic, L., & Kuliopulos, A. (2007) · Nature Immunology · doi:10.1038/ni1525 · Cited by 233
Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells
Nobles, M., Benians, A., & Tinker, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504778102 · Cited by 222 · cited 1×
“These data are consistent with the notion that GPCRs may be precoupled to G protein, even before activation (41, 56, 57).”
BackgroundCheng, Z.-J., Zhao, J., Sun, Y., Hu, W., Wu, Y.-L., Cen, B., Wu, G.-X., & Pei, G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2479 · Cited by 219 · cited 1×
“In addition to its coupling to Gi, CXCR4 has also been found to signal through the engagement and activation of G13 (37, 38) and β-arrestin2 (39, 40), both pathways being proposed to contribute to the chemotactic responses.”
BackgroundBlocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis
Leger, A. J., Jacques, S. L., Badar, J., Kaneider, N. C., Derian, C. K., Andrade-Gordon, P., Covic, L., & Kuliopulos, A. (2006) · Circulation · doi:10.1161/circulationaha.105.587758 · Cited by 218 · cited 2×
“Pepducins have been identified for several GPCRs, including the proteaseactivated receptors PAR1 (1, 4–10), PAR2 (1, 11–13), and PAR4 (6, 9), the formyl peptide receptor-2 (14), the melanocortin type 4 receptor (1), the sphingosine 1-phosphate receptor 3 (15), and the C-X-C chemokine receptor type 1, 2 (CXCR1, CXCR2)…”
BackgroundAripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways
Urban, J. D., Vargas, G. A., von Zastrow, M., & Mailman, R. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301071 · Cited by 197
Role of the intracellular domains of CXCR4 in SDF-1–mediated signaling
Roland, J., Murphy, B. J., Ahr, B., Robert-Hebmann, V., Delauzun, V., Nye, K. E., Devaux, C., & Biard-Piechaczyk, M. (2003) · Blood · doi:10.1182/blood-2002-03-0978 · Cited by 171 · cited 1×
“When assessing the effect of ATI-2341 on the signaling activity of CXCR4, the pepducin was found to be an allosteric agonist, activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization (18, 31).”
BackgroundThe Gα13-Rho Signaling Axis Is Required for SDF-1-induced Migration through CXCR4
Tan, W., Martín, D., & Gutkind, J. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609062200 · Cited by 169
O'Callaghan, K., Kuliopulos, A., & Covic, L. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.355461 · Cited by 157 · cited 2×
“Although the precise mode of action is not completely understood, it is believed that pepducins bind to their target receptors and allosterically modulate their signaling activity (2, 3).”
BackgroundYagi, H., Tan, W., Dillenburg-Pilla, P., Armando, S., Amornphimoltham, P., Simaan, M., Weigert, R., Molinolo, A. A., Bouvier, M., & Gutkind, J. S. (2011) · Science Signaling · doi:10.1126/scisignal.2002221 · Cited by 142 · cited 4×
“Interestingly, Gα13/Rho axis has recently been implicated in CXCR4-mediated chemotaxis and migration of metastatic breast cancer cells (38).”
BackgroundInfluentialSelf-citationReversing systemic inflammatory response syndrome with chemokine receptor pepducins
Kaneider, N. C., Agarwal, A., Leger, A. J., & Kuliopulos, A. (2005) · Nature Medicine · doi:10.1038/nm1245 · Cited by 137
Chemokine Regulation of Normal and Pathologic Immune Responses
Christopherson, K., & Hromas, R. (2001) · STEM CELLS · doi:10.1634/stemcells.19-5-388 · Cited by 137
Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins
Sevigny, L. M., Zhang, P., Bohm, A., Lazarides, K., Perides, G., Covic, L., & Kuliopulos, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017091108 · Cited by 120
Agarwal, A., Tressel, S. L., Kaimal, R., Balla, M., Lam, F. H., Covic, L., & Kuliopulos, A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4341 · Cited by 119 · cited 1×
“Pepducins have been identified for several GPCRs, including the proteaseactivated receptors PAR1 (1, 4–10), PAR2 (1, 11–13), and PAR4 (6, 9), the formyl peptide receptor-2 (14), the melanocortin type 4 receptor (1), the sphingosine 1-phosphate receptor 3 (15), and the C-X-C chemokine receptor type 1, 2 (CXCR1, CXCR2)…”
BackgroundDiscovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells
Tchernychev, B., Ren, Y., Sachdev, P., Janz, J. M., Haggis, L., O’Shea, A., McBride, E., Looby, R. J., Deng, Q., McMurry, T. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009633108 · Cited by 109 · cited 9×
“Of note, unlike the clinically used CXCR4 antagonist AMD-3100 and stromal cell-derived factor-1α (SDF-1; also known as CXCL12) that promote the mobilization of lymphocytes in addition to PMNs and HSPCs (18, 28–30), ATI-2341 was without effect on the mobilization of lymphocytes (18), indicating that ATI-2341 may displa…”
BackgroundMethodResultInfluentialSelf-citationLicht, T., Tsirulnikov, L., Reuveni, H., Yarnitzky, T., & Ben‐Sasson, S. A. (2003) · Blood · doi:10.1182/blood-2002-12-3634 · Cited by 105
Goupil, E., Tassy, D., Bourguet, C. B., Quiniou, C., Wisehart, V., Pétrin, D., Gouill, C. L., Devost, D., Zingg, H. H., Bouvier, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.115196 · Cited by 100
Self-citationTargeting Protease-Activated Receptor-1 with Cell-Penetrating Pepducins in Lung Cancer
Cisowski, J., O’Callaghan, K., Kuliopulos, A., Yang, J., Nguyen, N., Deng, Q., Yang, E., Fogel, M. A., Tressel, S. L., Foley, C., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.03.025 · Cited by 95 · cited 2×
“(5) found that a pepducin derived from the third intracellular loop fully inhibited cell motility, calcium mobilization, and ERK1/2 activation proA”
BackgroundSelf-citationHamdan, F. F., Rochdi, M. D., Breton, B., Fessart, D., Michaud, D. E., Charest, P. G., Laporte, S. A., & Bouvier, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700577200 · Cited by 91
Self-citationMobilization and Homing of Hematopoietic Stem Cells
Suárez-Álvarez, B., López-Vázquez, A., & López-Larrea, C. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-2098-9_11 · Cited by 90
Zhang, P., Gruber, A., Kasuda, S., Kimmelstiel, C. D., O’Callaghan, K., Cox, D. H., Bohm, A., Baleja, J., Covic, L., & Kuliopulos, A. (2012) · Circulation · doi:10.1161/circulationaha.112.091918 · Cited by 88
Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors
Stallaert, W., Christopoulos, A., & Bouvier, M. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.586691 · Cited by 81
Self-citationMobilization of hematopoietic stem cells from the bone marrow niche to the blood compartment
Hoggatt, J., & Pelus, L. M. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt54 · Cited by 79
Mohty, M., Duarte, R. F., Croockewit, S., Hübel, K., Kvalheim, G., & Russell, N. H. (2011) · Leukemia · doi:10.1038/leu.2010.224 · Cited by 75 · cited 1×
“A CXCR4 antagonist, AMD-3100 (Mozobil), is used to mobilize HSPCs from the bone marrow for transplantation of leukemic patients (27).”
BackgroundSignificant mobilization of both conventional and regulatory T cells with AMD3100
Kean, L. S., Sen, S., Onabajo, O. O., Singh, K., Robertson, J. M., Stempora, L., Bonifacino, A. C., Metzger, M. E., Promislow, D., Mattapallil, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-06-359331 · Cited by 74
Direct Interaction between an Allosteric Agonist Pepducin and the Chemokine Receptor CXCR4
Janz, J. M., Ren, Y., Looby, R. J., Kazmi, M. A., Sachdev, P., Grunbeck, A., Haggis, L., Chinnapen, D. J. ‐., Lin, A. Y. J., Seibert, C., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja206661w · Cited by 71 · cited 4×
“Although the precise mode of action is not completely understood, it is believed that pepducins bind to their target receptors and allosterically modulate their signaling activity (2, 3).”
BackgroundMethodInfluentialSelf-citationTargeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia
O’Callaghan, K., Lee, L., Nguyen, N., Hsieh, M.-Y., Kaneider, N. C., Klein, A. K., Sprague, K., Etten, R. A. V., Kuliopulos, A., & Covic, L. (2011) · Blood · doi:10.1182/blood-2011-04-347518 · Cited by 71 · cited 2×
“Pepducins have been identified for several GPCRs, including the proteaseactivated receptors PAR1 (1, 4–10), PAR2 (1, 11–13), and PAR4 (6, 9), the formyl peptide receptor-2 (14), the melanocortin type 4 receptor (1), the sphingosine 1-phosphate receptor 3 (15), and the C-X-C chemokine receptor type 1, 2 (CXCR1, CXCR2)…”
BackgroundThe Ins and Outs of Hematopoietic Stem Cells: Studies to Improve Transplantation Outcomes
Marquez‐Curtis, L. A., Turner, A. R., Sridharan, S., Ratajczak, M. Z., & Janowska‐Wieczorek, A. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9212-8 · Cited by 64
Choi, W., & An, J. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.010389 · Cited by 59 · cited 4×
“This receptor, expressed in many tissues including hematopoietic and circulating cells, is a coreceptor for the entry of HIV (19, 20) and controls many physiological functions, including cell migration, mobilization, and retention of polymorphonuclear neutrophils (PMNs) and hematopoietic stem cells, as well as progeni…”
BackgroundInfluentialKaufmann, R., Oettel, C., Horn, A., Halbhuber, K. J., Eitner, A., Krieg, R., Katenkamp, K., Henklein, P., Westermann, M., Böhmer, F. D., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp153 · Cited by 47
Tsuji, M., Ueda, S., Hirayama, T., Okuda, K., Sakaguchi, Y., Isono, A., & Nagasawa, H. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob27445d · Cited by 41 · cited 8×
“BRET | lipid-anchored peptide | beta-arrestin | protein–protein interaction | cell signaling Pepducins represent a class of molecules that regulate theactivity of G protein-coupled receptors (GPCRs).”
BackgroundInfluentialKubo, S., Ishiki, T., Doe, I., Sekiguchi, F., Nishikawa, H., Kawai, K., Matsui, H., & Kawabata, A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.087 · Cited by 32
Activation of human monocytes by a formyl peptide receptor 2‐derived pepducin
Lee, H. Y., Kim, S. D., Shim, J. W., Kim, H. J., Kwon, J. Y., Kim, J., Baek, S., Park, J. S., & Bae, Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.08.036 · Cited by 32 · cited 1×
“Pepducins have been identified for several GPCRs, including the proteaseactivated receptors PAR1 (1, 4–10), PAR2 (1, 11–13), and PAR4 (6, 9), the formyl peptide receptor-2 (14), the melanocortin type 4 receptor (1), the sphingosine 1-phosphate receptor 3 (15), and the C-X-C chemokine receptor type 1, 2 (CXCR1, CXCR2)…”
BackgroundSroussi, H., Lu, Y., Villines, D. C., & Sun, Y. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.12.001 · Cited by 27
Subtype Differences in Pre-Coupling of Muscarinic Acetylcholine Receptors
Jakubík, J., Janíčková, H., Randáková, A., El‐Fakahany, E. E., & Doležal, V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027732 · Cited by 18 · cited 1×
“These data are consistent with the notion that GPCRs may be precoupled to G protein, even before activation (41, 56, 57).”
Background
Cited by
Biased signalling: from simple switches to allosteric microprocessors
Smith, J. S., Lefkowitz, R. J., & Rajagopal, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.229 · Cited by 738
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
Biased ligands at G-protein-coupled receptors: promise and progress
Violin, J. D., Crombie, A. L., Soergel, D. G., & Lark, M. W. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.007 · Cited by 363
Namkung, Y., Le Gouill, C., Lukashova, V., Kobayashi, H., Hogue, M., Khoury, E., Song, M., Bouvier, M., & Laporte, S. A. (2016) · Nature Communications · doi:10.1038/ncomms12178 · Cited by 347
Self-citationAvet, C., Mancini, A., Breton, B., Le Gouill, C., Hauser, A. S., Normand, C., Kobayashi, H., Gross, F., Hogue, M., Lukasheva, V., et al. (2022) · eLife · doi:10.7554/elife.74101 · Cited by 267
Self-citation
Metadata
- Authors
- Quoyer, J., Janz, J. M., Luo, J., Ren, Y., Armando, S., Lukashova, V., Benovic, J. L., Carlson, K. E., Hunt, S. W., & Bouvier, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-12-05
- Volume
- 110
- Issue
- 52
- Pages
- E5088-97
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2070493428
- Cited by
- 173
- References
- 58
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.